|
|
|
|
|
|
|
|
European Journal of Cancer Prevention:
Abstract
Population-based studies on ovarian cancer providing
survival estimates by age, histology, laterality, and stage have been
sparse. We aimed to derive the most up-to-date and detailed survival
estimates for ovarian cancer patients in Germany. We used a pooled
German national dataset including data from 11 cancer registries
covering 33 million populations. A total of 21 651 patients diagnosed
with ovarian cancer in 1997-2006 were included. Period analysis was
carried out to calculate the 5-year relative survival (RS) for the years
2002-2006. Trends in survival between 2002 and 2006 were examined using
model-based period analysis. Age adjustment was performed using five
age groups (15-44, 45-54, 55-64, 65-74, and 75+ years). Overall, the
age-adjusted 5-year RS in 2002-2006 was 41%. A strong age gradient was
observed, with a decrease in the 5-year RS from 67% in the age group
15-49 years to 28% in the age group 70+ years. Furthermore, the
prognosis varied markedly by histology, laterality, and stage, with the
age-adjusted 5-year RS ranging from 25% (for carcinoma not otherwise
specified) to 81% (for stromal cell carcinoma), reaching 46% for
unilateral and 32% for bilateral carcinoma and reaching 82% for
Federation of Gynecology and Obstetrics (FIGO) stages I and II, 36% for
FIGO stage III, and 18% for FIGO stage IV. No improvement in survival
could be observed for any of the subgroups in the period between 2002
and 2006. Our analyses suggest that an improvement in the 5-year RS for
ovarian cancer may have stagnated in the early 21st century and
underline the need for a more effective translation of therapeutic
innovation into clinical practice.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.